Dogwood Therapeutics, Inc. (DWTX)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

1.40 on 9 Oct 2026

0 buys0 sales at will0 planned sales

Fiscal year 2025, ended 31 Dec 2025, as filed

Net income

$34.26M

Free cash flow

$15.62M

Return on equity

-45.7%

Return on capital

-29.5%

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
21 Aug 2023	Pridgen William Director	Bought	$19.99K	41.8%
17 Aug 2023	Duncan Gregory Scott CHIEF EXECUTIVE OFFICER	Bought	$31.25K	77.0%
8 Dec 2022	Whitley Richard James Director	Sold, plan not stated	$466.38	72.0%
23 May 2022	Duncan Gregory Scott CHIEF EXECUTIVE OFFICER	Bought	$33.90K	30.0%
23 May 2022	Walsh Angela SVP OF FINANCE	Bought	$9.15K	200%
18 May 2022	Whitley Richard James Director	Bought	$2.26K	25.0%

33out of 100

Profitability 0

Financial strength 60

Growth n/a

Insiders 50

Strongest on financial strength (60), weakest on profitability (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$0.00

0 buys, 0 buyers

Sold

$0.00

0 sales

Planned sales

n/a

under a 10b5-1 plan